Compounds > bisoprolol
Page last updated: 2024-10-23

bisoprolol and Atrial Fibrillation

bisoprolol has been researched along with Atrial Fibrillation in 52 studies

Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.

Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.

Research Excerpts

ExcerptRelevanceReference
"Among patients with permanent atrial fibrillation and symptoms of heart failure treated with low-dose digoxin or bisoprolol, there was no statistically significant difference in quality of life at 6 months."9.34Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. ( Bunting, KV; Calvert, MJ; Camm, AJ; Deeks, JJ; Gill, SK; Griffith, M; Haynes, S; Jones, JC; Kirchhof, P; Kotecha, D; Lip, GYH; Mehta, S; Rahimi, K; Stanbury, M; Steeds, RP; Strauss, VY; Townend, JN, 2020)
"We previously performed a trial of intravenous landiolol hydrochloride during and after cardiac surgery (the PASCAL trial) and demonstrated a preventive effect on postoperative atrial fibrillation (AF)."9.16Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. ( Hata, M; Hirayama, A; Kunimoto, S; Nakai, T; Sezai, A; Shiono, M; Yoshitake, I, 2012)
" We evaluated the antiarrhythmic effects of a highly selective beta(1)-blocker, bisoprolol, in patients with diurnal paroxysmal atrial fibrillation (P-AF)."9.13Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. ( Abe, A; Ikeda, T; Ishiguro, H; Mera, H; Nakamura, K; Tsukada, T; Yoshino, H; Yusu, S, 2008)
"Ninety patients who underwent cardioversion of persistent atrial fibrillation (AF) were randomized to bisoprolol 5 to 10 mg once daily or carvedilol 12."9.10Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. ( Anagnostopoulos, CE; Camm, AJ; Giazitzoglou, E; Karvouni, E; Katritsis, DG; Korovesis, S; Panagiotakos, DB; Paxinos, G, 2003)
"The purpose of the study was to compare the efficacy and safety of sotalol and bisoprolol in the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation."9.09Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. ( Alt, EU; Lehmann, G; Ndrepepa, G; Plewan, A; Schmitt, C; Schömig, A; Schreieck, J, 2001)
"We compared the efficacy of perioperative ivabradine, bisoprolol, or both for prevention of postoperative atrial fibrillation (AF) in patients undergoing coronary artery bypass grafting (CABG)."7.83Atrial Fibrillation After Coronary Artery Bypass Surgery: Can Ivabradine Reduce Its Occurrence? ( Abdel-Salam, Z; Nammas, W, 2016)
"Although carvedilol and bisoprolol are effective medicines for the treatment of patients with heart failure (HF), only a few reports have compared their effects."7.76Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. ( Hachiya, H; Haraguchi, G; Hirao, K; Inagaki, H; Isobe, M; Kawabata, M; Kimura, S; Konishi, M, 2010)
" The incidence of adverse events did not differ between the groups."6.90Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study). ( Akita, Y; Ikeda, T; Yamashita, T, 2019)
"Bisoprolol was started at 1."6.76Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. ( Arisi, G; Caminiti, G; Iellamo, F; Madonna, M; Marazzi, G; Massaro, R; Righi, D; Rosano, GM; Volterrani, M, 2011)
"Treatment with bisoprolol resulted in a trend to lower ventricular response rate in AF cases."6.74Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary artery bypass graft surgery: a prospective randomized trial. ( Ashoush, R; El Rassi, I; Haddad, F; Hayeck, G; Jebara, V; Madi-Jebara, S; Sleilaty, G; Yazigi, A, 2009)
"Thyroid storm is a life-threatening disorder that remains a therapeutic challenge."5.46Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction. ( Fujita, M; Godo, S; Kawazoe, Y; Kudo, D; Kushimoto, S; Nomura, R; Ozaki, H; Shimokawa, H, 2017)
"We examined the efficacy of TDPB for paroxysmal atrial fibrillation (PAF) after open heart surgery."5.46[Efficacy of Transdermal Patch of Bisoprolol for Paroxysmal Atrial Fibrillation after Open Heart Surgery]. ( Enomoto, S; Hamuro, M; Kawatou, M; Yamada, T; Yamamoto, K, 2017)
"The bisoprolol patch was introduced 88 h after the start of landiolol administration, when the rate was approximately 3 μg/kg/min."5.43Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. ( Doi, K; Hiruma, T; Inokuchi, R; Nakajima, S; Nakamura, K; Tokunaga, K, 2016)
"Among patients with permanent atrial fibrillation and symptoms of heart failure treated with low-dose digoxin or bisoprolol, there was no statistically significant difference in quality of life at 6 months."5.34Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. ( Bunting, KV; Calvert, MJ; Camm, AJ; Deeks, JJ; Gill, SK; Griffith, M; Haynes, S; Jones, JC; Kirchhof, P; Kotecha, D; Lip, GYH; Mehta, S; Rahimi, K; Stanbury, M; Steeds, RP; Strauss, VY; Townend, JN, 2020)
"The RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial will enrol 160 participants with a prospective, randomised, open-label, blinded end point design comparing initial rate control with digoxin or bisoprolol."5.24A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. ( Calvert, M; Deeks, JJ; Griffith, M; Kirchhof, P; Kotecha, D; Lip, GY; Mehta, S; Slinn, G; Stanbury, M; Steeds, RP; Townend, JN, 2017)
"Using the keywords "bisoprolol" and "arrhythmias" or "atrial fibrillation" or "ventricular tachycardia" or "premature ventricular complexes" or "ventricular fibrillation", the Medline database was searched for articles in English or French until April 2020 assessing the role of bisoprolol in the treatment of arrhythmias."5.22Beta-blockers for the treatment of arrhythmias: Bisoprolol - a systematic review. ( Cismaru, G; Gusetu, G; Mada, RO; Martins, RP; Muresan, C; Muresan, L; Puiu, M; Rosu, R, 2022)
"This pharmacogenetic substudy of the prospective, double-blind, randomized CIBIS-ELD trial determined the impact of the β1-adrenoceptor Arg189Gly polymorphism on heart-rate responses to bisoprolol or carvedilol in elderly patients with heart failure (421 with sinus rhythm, 107 with atrial fibrillation)."5.16Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. ( Apostolović, S; Dimković, S; Düngen, HD; Edelmann, F; Eschenhagen, T; Gelbrich, G; Haverkamp, W; Lainščak, M; Nešković, AN; Rau, T; Waagstein, F, 2012)
"We previously performed a trial of intravenous landiolol hydrochloride during and after cardiac surgery (the PASCAL trial) and demonstrated a preventive effect on postoperative atrial fibrillation (AF)."5.16Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. ( Hata, M; Hirayama, A; Kunimoto, S; Nakai, T; Sezai, A; Shiono, M; Yoshitake, I, 2012)
" We evaluated the antiarrhythmic effects of a highly selective beta(1)-blocker, bisoprolol, in patients with diurnal paroxysmal atrial fibrillation (P-AF)."5.13Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. ( Abe, A; Ikeda, T; Ishiguro, H; Mera, H; Nakamura, K; Tsukada, T; Yoshino, H; Yusu, S, 2008)
"Ninety patients who underwent cardioversion of persistent atrial fibrillation (AF) were randomized to bisoprolol 5 to 10 mg once daily or carvedilol 12."5.10Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. ( Anagnostopoulos, CE; Camm, AJ; Giazitzoglou, E; Karvouni, E; Katritsis, DG; Korovesis, S; Panagiotakos, DB; Paxinos, G, 2003)
"The purpose of the study was to compare the efficacy and safety of sotalol and bisoprolol in the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation."5.09Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. ( Alt, EU; Lehmann, G; Ndrepepa, G; Plewan, A; Schmitt, C; Schömig, A; Schreieck, J, 2001)
"The transdermal formulation of bisoprolol may be useful for the early introduction of β-blockers in patients admitted with cardiac symptoms associated with myocardial ischemia or heart failure."4.02An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms. ( Horiuchi, N; Kobayashi, T; Kobayashi, Y; Nakamura, S; Nakanishi, H; Naruhashi, K; Nozaki, A; Okugawa, H, 2021)
" We report a case of bisoprolol-induced bradycardia in an elderly patient with impaired renal function and use of cytochrome P450 inhibitors."3.88[Pharmacokinetic risk factors of beta-blockers overdose in the elderly: Case report and pharmacology approach]. ( Bernard, N; Bourguignon, L; De La Gastine, B; Dehan-Moya, MJ; Goutelle, S; Lafarge, L; Vial, T, 2018)
"We compared the efficacy of perioperative ivabradine, bisoprolol, or both for prevention of postoperative atrial fibrillation (AF) in patients undergoing coronary artery bypass grafting (CABG)."3.83Atrial Fibrillation After Coronary Artery Bypass Surgery: Can Ivabradine Reduce Its Occurrence? ( Abdel-Salam, Z; Nammas, W, 2016)
"Although carvedilol and bisoprolol are effective medicines for the treatment of patients with heart failure (HF), only a few reports have compared their effects."3.76Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. ( Hachiya, H; Haraguchi, G; Hirao, K; Inagaki, H; Isobe, M; Kawabata, M; Kimura, S; Konishi, M, 2010)
" The incidence of adverse events did not differ between the groups."2.90Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study). ( Akita, Y; Ikeda, T; Yamashita, T, 2019)
"Bisoprolol was started at 1."2.76Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. ( Arisi, G; Caminiti, G; Iellamo, F; Madonna, M; Marazzi, G; Massaro, R; Righi, D; Rosano, GM; Volterrani, M, 2011)
"Treatment with bisoprolol resulted in a trend to lower ventricular response rate in AF cases."2.74Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary artery bypass graft surgery: a prospective randomized trial. ( Ashoush, R; El Rassi, I; Haddad, F; Hayeck, G; Jebara, V; Madi-Jebara, S; Sleilaty, G; Yazigi, A, 2009)
"Heart failure is a serious disorder associated with substantial morbidity and mortality."2.42Role of beta-blocker therapy in heart failure and atrial fibrillation. ( Fung, JW; Kum, LC; Sanderson, JE; Yip, GW; Yu, CM, 2003)
"Fifteen patients experienced persistent atrial fibrillation and were treated with electrical cardioversion during hospitalization."1.91Managing postoperative atrial fibrillation after open-heart surgery using transdermal β ( Enomoto, S; Hamuro, M; Kurokawa, S; Miwa, S; Setozaki, S; Yamada, T; Yamamoto, K, 2023)
"Bradycardia is a significant cause of hospital admissions in older adults and can be avoided with pharmacovigilance."1.72Drug-related bradycardia precipitating hospital admission in older adults: an ongoing problem. ( Amin, FR; Dickinson, B; Griffiths, C; Ioannou, A; Mandal, AKJ; Metaxa, S; Missouris, CG, 2022)
"Thyroid storm is a life-threatening disorder that remains a therapeutic challenge."1.46Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction. ( Fujita, M; Godo, S; Kawazoe, Y; Kudo, D; Kushimoto, S; Nomura, R; Ozaki, H; Shimokawa, H, 2017)
"We examined the efficacy of TDPB for paroxysmal atrial fibrillation (PAF) after open heart surgery."1.46[Efficacy of Transdermal Patch of Bisoprolol for Paroxysmal Atrial Fibrillation after Open Heart Surgery]. ( Enomoto, S; Hamuro, M; Kawatou, M; Yamada, T; Yamamoto, K, 2017)
"The bisoprolol patch was introduced 88 h after the start of landiolol administration, when the rate was approximately 3 μg/kg/min."1.43Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. ( Doi, K; Hiruma, T; Inokuchi, R; Nakajima, S; Nakamura, K; Tokunaga, K, 2016)
"A case of pseudo-ventricular tachycardia is outlined in a patient with newly diagnosed atrial fibrillation, which made the diagnosis a special challenge."1.40Pseudo-ventricular tachycardia mimicking malignant arrhythmia in a patient with rapid atrial fibrillation. ( Barake, W; Baranchuk, A; Pinter, A, 2014)
"A couple of days after increasing the dosage of betaadrenergic- and adding calcium channel blockers due to an increased heart rate in atrial fibrillation, a 77 year old female was found in cardiogenic shock."1.38[The choked heart]. ( Furrer, F; Giambarba, C, 2012)

Research

Studies (52)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (1.92)18.2507
2000's15 (28.85)29.6817
2010's24 (46.15)24.3611
2020's12 (23.08)2.80

Authors

AuthorsStudies
Muresan, L1
Cismaru, G1
Muresan, C1
Rosu, R1
Gusetu, G1
Puiu, M1
Mada, RO1
Martins, RP1
Yamamoto, K2
Miwa, S1
Yamada, T2
Setozaki, S1
Hamuro, M2
Kurokawa, S1
Enomoto, S2
Kanorskiy, SG1
Polischuk, LV1
Nozaki, A1
Kobayashi, T1
Naruhashi, K1
Okugawa, H1
Horiuchi, N1
Nakanishi, H1
Kobayashi, Y1
Nakamura, S1
Curfman, G1
Kotecha, D3
Bunting, KV1
Gill, SK1
Mehta, S2
Stanbury, M2
Jones, JC1
Haynes, S1
Calvert, MJ1
Deeks, JJ2
Steeds, RP2
Strauss, VY1
Rahimi, K1
Camm, AJ2
Griffith, M2
Lip, GYH1
Townend, JN2
Kirchhof, P2
Griffiths, C1
Ioannou, A1
Dickinson, B1
Metaxa, S1
Amin, FR1
Mandal, AKJ1
Missouris, CG1
Steurer, J1
Garg, J1
Gopinathannair, R1
Lakkireddy, D1
Karimzad, K1
Deswal, A1
Iwano, T1
Toda, H1
Nakamura, K3
Shimizu, K1
Ejiri, K1
Naito, Y1
Mori, H1
Masuda, T1
Miyoshi, T1
Yoshida, M1
Hikasa, Y1
Morimatsu, H1
Ito, H1
Mulder, BA1
Damman, K1
Van Veldhuisen, DJ1
Van Gelder, IC1
Rienstra, M1
Calvert, M1
Lip, GY1
Slinn, G1
Godo, S1
Kawazoe, Y1
Ozaki, H1
Fujita, M1
Kudo, D1
Nomura, R1
Shimokawa, H1
Kushimoto, S1
Kawatou, M1
Lafarge, L1
Bourguignon, L1
Bernard, N1
Vial, T1
Dehan-Moya, MJ1
De La Gastine, B1
Goutelle, S1
Yamashita, T2
Ikeda, T2
Akita, Y1
Palmer, J1
Sizer, AR1
Inoue, H1
Bradley, A1
Sheridan, P1
Barake, W1
Baranchuk, A1
Pinter, A1
Jackson, MW1
Taylor, RJ1
Abdel-Salam, Z1
Nammas, W1
Ji, T1
Feng, C1
Sun, L1
Ye, X1
Bai, Y1
Chen, Q1
Qin, Y1
Zhu, J1
Zhao, X1
Inokuchi, R1
Hiruma, T1
Tokunaga, K1
Doi, K1
Nakajima, S1
Lu, HT1
Nordin, R1
Othman, N1
Choy, CN1
Kam, JY1
Leo, BC1
Ramsamy, G1
Goh, TH1
Ishiguro, H1
Abe, A1
Tsukada, T1
Mera, H1
Yusu, S1
Yoshino, H1
Sleilaty, G1
Madi-Jebara, S1
Yazigi, A1
Haddad, F1
Hayeck, G1
El Rassi, I1
Ashoush, R1
Jebara, V1
Konishi, M1
Haraguchi, G1
Kimura, S1
Inagaki, H1
Kawabata, M1
Hachiya, H1
Hirao, K1
Isobe, M1
González Oliva, JC1
Saurina i Solé, A1
Pou Potau, M1
Salas Gama, KR1
Ramírez de Arellano Serna, M1
Marazzi, G1
Iellamo, F1
Volterrani, M1
Caminiti, G1
Madonna, M1
Arisi, G1
Massaro, R1
Righi, D1
Rosano, GM1
Yanagisawa, S1
Suzuki, N1
Tanaka, T1
Rau, T2
Düngen, HD2
Edelmann, F2
Waagstein, F1
Lainščak, M2
Dimković, S1
Apostolović, S2
Nešković, AN2
Haverkamp, W1
Gelbrich, G2
Eschenhagen, T1
Stankovic, I1
Putnikovic, B1
Doehner, W1
Inkrot, S1
Herrmann-Lingen, C1
Anker, SD1
Meinertz, T1
Furrer, F1
Giambarba, C1
Sezai, A1
Nakai, T1
Hata, M1
Yoshitake, I1
Shiono, M1
Kunimoto, S1
Hirayama, A1
Yoshiga, Y1
Shimizu, A1
Yamagata, T1
Hayano, T1
Ueyama, T1
Ohmura, M1
Itagaki, K1
Kimura, M1
Matsuzaki, M1
Schrickel, J1
Bielik, H1
Yang, A1
Schwab, JO1
Shlevkov, N1
Schimpf, R1
Lüderitz, B1
Lewalter, T1
Katritsis, DG2
Panagiotakos, DB1
Karvouni, E1
Giazitzoglou, E1
Korovesis, S1
Paxinos, G1
Anagnostopoulos, CE1
Fung, JW1
Yu, CM1
Kum, LC1
Yip, GW1
Sanderson, JE1
Tereshchenko, SN2
Bulanova, NA1
Kositsyna, IV1
Morozova, MN2
Uteshev, IuA2
Kowey, PR1
Kneissl, GD1
Burger, W1
Meixensberger, J1
Friedrich, F1
Kortmann, RD1
Hohnloser, SH1
Dorian, P1
Roberts, R1
Gent, M1
Israel, CW1
Fain, E1
Champagne, J1
Connolly, SJ1
Behmanesh, S1
Tossios, P1
Homedan, H1
Hekmat, K1
Hellmich, M1
Müller-Ehmsen, J1
Schwinger, RH1
Mehlhorn, U1
Chuich, NG1
Kochetov, AG1
van den Berg, MP1
van de Ven, LL1
Witting, W1
Crijns, HJ1
Haaksma, J1
Bel, KJ1
de Langen, CD1
Lie, KI1
Plewan, A1
Lehmann, G1
Ndrepepa, G1
Schreieck, J1
Alt, EU1
Schömig, A1
Schmitt, C1
Burri, H1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337]Phase 120 participants (Anticipated)Interventional2023-02-06Recruiting
Left Atrium Reservoir Function Modulation in Patients With Atrial Fibrillation: A Randomized Digoxin Versus Beta Blocker Study[NCT05540600]Phase 330 participants (Anticipated)Interventional2022-09-12Recruiting
Evaluating Different Rate Control Therapies in Permanent Atrial Fibrillation: A Prospective, Randomised, Open-label, Blinded Endpoint Feasibility Pilot Comparing Digoxin and Beta-blockers as Initial Rate Control Therapy[NCT02391337]Phase 4161 participants (Actual)Interventional2016-12-20Completed
Multi-Disciplinary Rehabilitation Program in Recently Hospitalized Patients With Preserved Ejection Fraction Heart Failure[NCT01914315]1,100 participants (Anticipated)Interventional2013-10-31Recruiting
aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980]500 participants (Anticipated)Observational2015-01-01Recruiting
[NCT00257959]Phase 4400 participants Interventional2001-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Ambulatory Heart-rate.

24 hour ambulatory heart-rate. (NCT02391337)
Timeframe: Within 12 months

Interventionbpm (Mean)
Beta-blocker73.7
Digoxin78.9

B-type Natriuretic Peptide (BNP) at 6 Months.

B-type natriuretic peptide (BNP) at 6 months. (NCT02391337)
Timeframe: 6 months

Interventionng/L (Median)
Beta-blocker1209
Digoxin1057.5

Cardiovascular Events

Number of Participants with hospital admissions for cardiovascular events. (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Beta-blocker12
Digoxin2

Composite Functional Status Measures- 6 Minute Walking Distance at 12 Months.

Composite functional status measures- 6 minute walking distance at 12 months. (NCT02391337)
Timeframe: 12 months

Interventionmetres (Median)
Beta-blocker329
Digoxin366

Diastolic Function- Measured by the E/e'.

"The above parameters will be measured using echocardiography and diastolic indices.~E/e' - the ratio between early mitral inflow velocity and mitral annular early diastolic velocity." (NCT02391337)
Timeframe: 12 months

InterventionRatio of E/e' (Mean)
Beta-blocker10.8
Digoxin10.8

Drug Discontinuation Rate Within 12 Months.

Number of participants requiring drug discontinuation due to adverse reactions. (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Beta-blocker9
Digoxin2

Hospital Admission Rate

A composite of adverse clinical events (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Beta-blocker19
Digoxin11

Left Ventricular Ejection Fraction

The above parameters will be measured using echocardiography and diastolic indices (NCT02391337)
Timeframe: 12 months

Interventionpercentage of ejection fraction (Mean)
Beta-blocker59.8
Digoxin59.7

Number of Participants With Unplanned Hospital Admissions.

Number of Participants with Unplanned Hospital Admissions. (NCT02391337)
Timeframe: During the 12 month follow-up period.

InterventionParticipants (Count of Participants)
Beta-blocker19
Digoxin11

Patient Reported Outcomes (EQ-5D-5L)

"As assessed using the EQ-5D-5L summary index questionnaires at both 6 and 12 months.~The range for summary index is from -0.594=worst score to 1=best score" (NCT02391337)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Beta-blocker0.62
Digoxin0.66

Patient Reported Outcomes- (AFEQT) at 12 Months.

As assessed using the AFEQT overall score at 12 months. The range for AFEQT overall score is from 0= complete disability to 100=no disability. (NCT02391337)
Timeframe: 12 months

Interventionscore on a scale (Mean)
Beta-blocker68.1
Digoxin75.6

Patient Reported Quality of Life (SF-36)

"Patient-reported outcomes as assessed by the SF-36 questionnaire physical component score.~The physical component score ranges from 0-100 where higher value indicates better outcome." (NCT02391337)
Timeframe: Primary outcome at 6 months timepoint.

Interventionscore on a scale (Mean)
Beta-blocker29.7
Digoxin31.9

Patient Reported Outcomes (SF36) Version 2 at 12 Months.

As assessed using the SF-36 version 2 global and specific scores at 12 months. All domains presented are between 0 to 100 scale where the higher score indicates better outcomes. (NCT02391337)
Timeframe: 12 months

,
Interventionscore on a scale (Mean)
Physical Component SummaryMental Component SummaryPhysical Function Domain ScoreRole Limitation Due to Physical Domain scoreRole Limitation Due to Emotional Problems Domain scoreSocial Functioning Domain ScoreMental Health DomainEnergy/Vitality Domain ScorePain ScoreGeneral Health Perception Domain Score
Beta-blocker29.451.327.53240.743.351.84241.939.6
Digoxin32.553.631.53745.245.651.347.140.542.8

Retention of Participants

Convenience, compliance and cross-over data (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Death71940422Death71940423Lost to follow-up71940422Lost to follow-up71940423Withdrawn consent71940422Withdrawn consent71940423
yesNo
Beta-blocker7
Digoxin4
Beta-blocker73
Digoxin77
Beta-blocker0
Digoxin2
Beta-blocker80
Beta-blocker1
Beta-blocker79
Digoxin79

Reviews

5 reviews available for bisoprolol and Atrial Fibrillation

ArticleYear
Beta-blockers for the treatment of arrhythmias: Bisoprolol - a systematic review.
    Annales pharmaceutiques francaises, 2022, Volume: 80, Issue:5

    Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Bisoprolol; Humans

2022
Are beta-blockers effective for preventing post-coronary artery bypass grafting atrial fibrillation? Direct and network meta-analyses.
    Irish journal of medical science, 2016, Volume: 185, Issue:2

    Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Bayes Theorem; Bisoprolol; Coronary Artery Bypass;

2016
Role of beta-blocker therapy in heart failure and atrial fibrillation.
    Cardiac electrophysiology review, 2003, Volume: 7, Issue:3

    Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Bisoprolol; Exercise Tolerance; Heart Failure; Hum

2003
[Chronic heart failure and atrial fibrilation: aspects of management].
    Kardiologiia, 2003, Volume: 43, Issue:10

    Topics: Acute Disease; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmi

2003
A review of carvedilol arrhythmia data in clinical trials.
    Journal of cardiovascular pharmacology and therapeutics, 2005, Volume: 10 Suppl 1

    Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca

2005

Trials

19 trials available for bisoprolol and Atrial Fibrillation

ArticleYear
[Control of ventricular rate in permanent atrial fibrillation: cardio-protec-tion and tissue hemodynamics].
    Kardiologiia, 2020, Mar-18, Volume: 60, Issue:3

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Bisoprolol; Heart Ventricles; Hemodynamics; Humans; Pr

2020
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
    JAMA, 2020, 12-22, Volume: 324, Issue:24

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr

2020
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
    JAMA, 2020, 12-22, Volume: 324, Issue:24

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr

2020
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
    JAMA, 2020, 12-22, Volume: 324, Issue:24

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr

2020
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
    JAMA, 2020, 12-22, Volume: 324, Issue:24

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr

2020
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
    JAMA, 2020, 12-22, Volume: 324, Issue:24

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr

2020
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
    JAMA, 2020, 12-22, Volume: 324, Issue:24

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr

2020
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
    JAMA, 2020, 12-22, Volume: 324, Issue:24

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr

2020
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
    JAMA, 2020, 12-22, Volume: 324, Issue:24

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr

2020
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
    JAMA, 2020, 12-22, Volume: 324, Issue:24

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibr

2020
Preventative effects of bisoprolol transdermal patches on postoperative atrial fibrillation in high-risk patients undergoing non-cardiac surgery: A subanalysis of the MAMACARI study.
    Journal of cardiology, 2021, Volume: 78, Issue:5

    Topics: Aged; Atrial Fibrillation; Bisoprolol; Humans; Postoperative Complications; Risk Factors; Stroke; Tr

2021
Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis.
    Clinical cardiology, 2017, Volume: 40, Issue:9

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Double-Blind Method;

2017
A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.
    BMJ open, 2017, Jul-20, Volume: 7, Issue:7

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolo

2017
Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study).
    Journal of cardiology, 2019, Volume: 73, Issue:5

    Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Asian People; Atrial Fibrillatio

2019
Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study.
    Journal of cardiology, 2013, Volume: 62, Issue:1

    Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Atrial Fibrillation; Bisoprolol; Blood Pressure

2013
Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation.
    International heart journal, 2008, Volume: 49, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Circadia

2008
Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary artery bypass graft surgery: a prospective randomized trial.
    International journal of cardiology, 2009, Oct-02, Volume: 137, Issue:2

    Topics: Administration, Oral; Aged; Amiodarone; Atrial Fibrillation; Bisoprolol; Coronary Artery Bypass; Fem

2009
Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.
    The American journal of cardiology, 2011, Jan-15, Volume: 107, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles

2011
Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.
    Clinical pharmacology and therapeutics, 2012, Volume: 92, Issue:1

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles; Carvedilo

2012
Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure--insight from the Cardiac Insufficiency Bisoprolol Study in Elderly.
    International journal of cardiology, 2012, Nov-29, Volume: 161, Issue:3

    Topics: Aged; Atrial Fibrillation; Bisoprolol; Double-Blind Method; Female; Follow-Up Studies; Heart Failure

2012
Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study.
    The Journal of thoracic and cardiovascular surgery, 2012, Volume: 144, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents;

2012
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.
    Circulation journal : official journal of the Japanese Circulation Society, 2002, Volume: 66, Issue:11

    Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Bisoprolol

2002
Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation.
    The American journal of cardiology, 2003, Nov-01, Volume: 92, Issue:9

    Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles; Carvedilol; Double-B

2003
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Circulation, 2006, Jul-11, Volume: 114, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol

2006
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Circulation, 2006, Jul-11, Volume: 114, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol

2006
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Circulation, 2006, Jul-11, Volume: 114, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol

2006
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Circulation, 2006, Jul-11, Volume: 114, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol

2006
Effect of prophylactic bisoprolol plus magnesium on the incidence of atrial fibrillation after coronary bypass surgery: results of a randomized controlled trial.
    Current medical research and opinion, 2006, Volume: 22, Issue:8

    Topics: Aged; Algorithms; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Coronary Artery Bypass; D

2006
[Effect of bisoprolol and sotalol on clinical status of patients with proximal form of atrial fibrillation and chronic heart failure].
    Kardiologiia, 2007, Volume: 47, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Fibrillation; Bisoprolol; Exercise Test; Female; He

2007
Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol.
    European heart journal, 2001, Volume: 22, Issue:16

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Electric Count

2001

Other Studies

28 other studies available for bisoprolol and Atrial Fibrillation

ArticleYear
Managing postoperative atrial fibrillation after open-heart surgery using transdermal β
    Journal of cardiothoracic surgery, 2023, Apr-06, Volume: 18, Issue:1

    Topics: Atrial Fibrillation; Bisoprolol; Cardiac Surgical Procedures; Electric Countershock; Heart Rate; Hum

2023
An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms.
    The American journal of emergency medicine, 2021, Volume: 39

    Topics: Acute Coronary Syndrome; Acute Disease; Administration, Cutaneous; Adrenergic beta-1 Receptor Antago

2021
Digitalis Glycosides for Heart Rate Control in Atrial Fibrillation.
    JAMA, 2020, 12-22, Volume: 324, Issue:24

    Topics: Atrial Fibrillation; Bisoprolol; Digitalis Glycosides; Digoxin; Heart Rate; Humans; Patient Reported

2020
Drug-related bradycardia precipitating hospital admission in older adults: an ongoing problem.
    European journal of hospital pharmacy : science and practice, 2022, Volume: 29, Issue:6

    Topics: Aged; Atrial Fibrillation; Bisoprolol; Bradycardia; Hospitals; Humans; Retrospective Studies

2022
    Praxis, 2021, Volume: 110, Issue:4

    Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Heart Failure; Humans

2021
Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation-Reply.
    JAMA, 2021, 04-27, Volume: 325, Issue:16

    Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Heart Rate; Humans

2021
Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation.
    JAMA, 2021, 04-27, Volume: 325, Issue:16

    Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Heart Rate; Humans; Patient Report

2021
In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo.
    Annals of internal medicine, 2021, Volume: 174, Issue:6

    Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Heart Rate; Humans; Quality

2021
Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction.
    Internal medicine (Tokyo, Japan), 2017, Oct-01, Volume: 56, Issue:19

    Topics: Administration, Cutaneous; Administration, Intravenous; Adrenergic beta-Antagonists; Adult; Atrial F

2017
[Efficacy of Transdermal Patch of Bisoprolol for Paroxysmal Atrial Fibrillation after Open Heart Surgery].
    Kyobu geka. The Japanese journal of thoracic surgery, 2017, Volume: 70, Issue:12

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atrial Fibrillation; Bisoprolol; Cardiac Surgical

2017
[Pharmacokinetic risk factors of beta-blockers overdose in the elderly: Case report and pharmacology approach].
    Annales de cardiologie et d'angeiologie, 2018, Volume: 67, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Aging; Atrial Fibrillation; Bisoprolol; Bradycardia;

2018
Recurrent lone atrial fibrillation in a twin pregnancy: a case report.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2019, Volume: 39, Issue:6

    Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Atrial Fibrillation; Bisoprolol; Female; Humans; Part

2019
Atrial fibrillation.
    BMJ (Clinical research ed.), 2013, Jun-17, Volume: 346

    Topics: Aged; Antihypertensive Agents; Anxiety; Atrial Fibrillation; Bisoprolol; Comorbidity; Diabetes Melli

2013
Pseudo-ventricular tachycardia mimicking malignant arrhythmia in a patient with rapid atrial fibrillation.
    American journal of critical care : an official publication, American Association of Critical-Care Nurses, 2014, Volume: 23, Issue:3

    Topics: Adrenergic beta-1 Receptor Antagonists; Artifacts; Atrial Fibrillation; Bisoprolol; Diagnosis, Diffe

2014
New-Onset Heart Failure in a Patient With a Pacemaker: An Unusual Cause.
    JAMA internal medicine, 2016, Volume: 176, Issue:1

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Atrial Fibrillation; Bisoprolol; Ca

2016
Atrial Fibrillation After Coronary Artery Bypass Surgery: Can Ivabradine Reduce Its Occurrence?
    Journal of cardiovascular electrophysiology, 2016, Volume: 27, Issue:6

    Topics: Action Potentials; Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibr

2016
Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia.
    Journal of anesthesia, 2016, Volume: 30, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B

2016
Biatrial thrombi resembling myxoma regressed after prolonged anticoagulation in a patient with mitral stenosis: a case report.
    Journal of medical case reports, 2016, Aug-10, Volume: 10, Issue:1

    Topics: Antihypertensive Agents; Atrial Fibrillation; Bisoprolol; Diagnosis, Differential; Directive Counsel

2016
Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure.
    Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:6

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Bisoprolol; Carbazoles; C

2010
[Difficult-to-treat atrial fibrillation in a patient on haemodialysis].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2010, Volume: 30, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Atrial Fibrillation; Bisoprolol; Bradycardia; Calcium

2010
Poor tolerance of beta-blockers by elderly patients with heart failure.
    Clinical interventions in aging, 2010, Nov-26, Volume: 5

    Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin Receptor Antagonists; Aortic Valve Steno

2010
[Supraventricular extrasystole after cardioversion with amiodarone].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:28-29

    Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Premature Complex

2012
[The choked heart].
    Praxis, 2012, Jul-04, Volume: 101, Issue:14

    Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Calcium Channel Blockers; Cardia

2012
Amiodarone-associated "torsade de pointes". Relevance of concomitant cardiovascular medication in a patient with atrial fibrillation and structural heart disease.
    Zeitschrift fur Kardiologie, 2003, Volume: 92, Issue:10

    Topics: Acetyldigoxins; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibril

2003
Anti-inflammatory medication for atrial fibrillation.
    European heart journal, 2004, Volume: 25, Issue:19

    Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Atrial Fibrillation; Bisoprolol; Carbazoles;

2004
Holiday heart syndrome possibly triggered after the start of radiochemotherapy for glioblastoma multiforme.
    Cardiology, 2006, Volume: 105, Issue:2

    Topics: Adrenergic beta-Antagonists; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bi

2006
Effects of beta-blockade on atrial and atrioventricular nodal refractoriness, and atrial fibrillatory rate during atrial fibrillation in pigs.
    Japanese heart journal, 1997, Volume: 38, Issue:6

    Topics: Adrenergic beta-Antagonists; Animals; Atrial Fibrillation; Atrioventricular Node; Bisoprolol; Catech

1997
Maintainance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation.
    European heart journal, 2002, Volume: 23, Issue:7

    Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Electric Countershock; Humans; Sotalol

2002